France: Transgene reaffirms financial visibility with sale of stake in Chinese company

Euronext Paris-listed Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, has sold its minority stake in a Chinese biopharmaceutical company to receive US$15.3m. Following this transaction, Transgene reaffirms its financial visibility until early 2024.  …

You must be a HMI Subscriber to view this content.

Subscribe Now »